



Abe Cabinet, announced long-term strategy of the 2025 “Innovation 25”. And he told 
to the center of the strategy to improve the innovation and productivity. On the basis of 
this opinion, he said it should be on the development of drugs and medical devices the 
center of the growth strategy.
By the way, Cameron Cabinet of the United Kingdom, have achieved economic growth 
above the peak of the economic crisis before. However, it is expected to stretch the width 
of the real income is small, productivity has not been much improvement, the future eco-
nomic growth of the UK to contract. And they have done a severe austerity also currently. 
Like Japan, in response to the aging of the population, the UK government, has continued 
to reduce health care costs, this has been going on from the Thatcher regime.
Under the environment of the market such as this, M & A of the leading pharmaceuti-
cal companies in the UK is deployed. It also analyzes the market trends that became this 
background, I have examined the investment promotion policy of pharmaceutical compa-
nies by the government. And I discussed was adopted for medical cost-containment mea-
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NHS歳出抑制政策（NHS expenditure control policies）
特許の崖（Cliff of patent）
ジェネリック医薬品の急速な成長（The rapid growth of the generic drug）
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